Physician profile
Toni Kim
NPI 1518003771
$160,360.37
in general payments reported to CMS, 2019-2025
24 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $1,034 · 2021: $337 · 2022: $4,452 · 2023: $54K · 2024: $60K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Travel and Lodging: $29K · Consulting Fee: $15K · Food and Beverage: $4,003 · Honoraria: $400 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,939.00 |
| Travel and Lodging | $28,999.07 |
| Consulting Fee | $14,864.00 |
| Food and Beverage | $4,002.71 |
| Honoraria | $400.00 |
| Education | $267.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $140,492.16 | 2022-2025 | Skytrofa |
| Neurocrine Biosciences, INC. | $10,975.96 | 2025 | |
| Pfizer INC. | $5,937.22 | 2019-2025 | |
| Novo Nordisk INC | $549.71 | 2019-2023 | Sogroya |
| Tolmar, INC. | $425.47 | 2023 | |
| Insulet Corporation | $356.34 | 2019-2020 | |
| Abbvie INC. | $341.80 | 2019-2023 | |
| Abbott Laboratories | $303.08 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $170.51 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $104.31 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $85.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $84.27 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $83.77 | 2020-2022 | |
| Dexcom, INC. | $80.02 | 2020-2021 | |
| Eton Pharmaceuticals, INC. | $68.96 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $62.75 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $59.50 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $45.98 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $34.73 | 2019-2020 | |
| Aegerion Pharmaceuticals, INC. | $23.67 | 2019 | |
| Biomarin Pharmaceutical INC. | $23.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.78 | 2021 | |
| Lilly USA, LLC | $16.20 | 2020 | |
| Medtronic Minimed, INC. | $15.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.